Loading…
← CockpitCompetitor Analysis › DMRA Damora Therapeutics, Inc.Open in the cockpit ↗

Damora Therapeutics, Inc.DMRACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Recently listed biotechnology company; specific pipeline and disease focus not confidently known.

Momentum neutral 41
Mkt cap
$1.42B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$11.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-117.1 pp
WACC 12.7%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$22.98
1D+1.9%
1W-1.2%
1M+11.2%
3M-24.2%
6M-4.8%
YTD-0.1%
1Y+0.6%
ATR %7.4%
Beta1.12
52w lowhigh40.0% off high

What Damora Therapeutics does

Recently listed biotechnology company; specific pipeline and disease focus not confidently known.

Where it sits in the supply chain

  • Pharmaceuticals
  • Clinical-stage biotech

Moat: none

Employees: 7

Damora Therapeutics at a glance

Size Damora Therapeutics (DMRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.42B, the 2002nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $22.98 on 18 Nov 2026.

Performance Over six months the shares fell 4.8%, against -14.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 20 in its peer set.

Capital Return on invested capital runs 117.1 points below its cost of capital (12.7% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026DMRA 92Peer median 88
Six months, rebased to 100: Damora Therapeutics against the median of its 20 peers (local-currency closes).

Damora Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$350,000-$34,000-$181,000-$830,000-$490,000
EBITDA-$130M-$36.5M-$16.7M-$35.6M-$60.7M
Net income-$292M-$210M-$21.4M-$38.3M-$61.6M
Free cash flow-$59.1M-$6.73M-$18.6M-$36.9M-$43.1M
Capital expenditure$0$0$0$0$196,000
Total debt$1.10M$1.41M$1.43M$249,000$804,000

Quarterly statements and history in the cockpit →

Damora Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-20%0%+20%4516MARKSANS310210140410PAHC002626002020CORONA141080226950NANO298380300181002099068760688293MNKDDMRA6-month return →1-month return →
Up and to the right = strong over both horizons. Damora Therapeutics is the large dot.

Damora Therapeutics competitors and peer comparison

How Damora Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Damora Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureDMRAPeer medianRank in peer set
1-month return+11.2%-3.7%4th highest of 20
6-month return-4.8%-14.6%9th highest of 20
Distance from 52-week high-40.0%-40.8%10th highest of 20
ROIC minus cost of capital-117.1 pp-0.5 pp3rd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%0.8×-18.1%+7.0%
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%3.8×31.0%+16.6%
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%85,633.6×n/an/a
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%216.0×n/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%1.4×-6.4%+12.7%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%3.1×n/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%8.9×36.3%+16.6%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%17.0×n/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%46.5×n/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%3.5×-4.9%+0.2%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%1.4×-6.1%+1.9%
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a

Questions

Which companies are Damora Therapeutics's closest peers?
The cockpit's peer set: Nippon Shinyaku (4516.T), Marksans Pharma (MARKSANS.NS), Voronoi (310210.KS), Mezzion Pharma (140410.KS), Phibro Animal Health (PAHC), Xiamen Kingdomway (002626.SZ), Zhejiang Jingxin Pharmaceutical (002020.SZ), Corona Remedies (CORONA.NS).
How has Damora Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -4.8% against -14.6% for the median peer; over one year +0.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.